NASDAQ: BRNSBarinthus Biotherapeutics PLC Stock
$2.43-0.08 (-3.19%)
Updated Apr 25, 2024
BRNS Price
$2.43
Fair Value Price
$3.22
Market Cap
$94.54M
52 Week Low
$1.64
52 Week High
$5.10
P/E
-1.27x
P/B
0.51x
P/S
176.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$802.00k
Earnings
-$73.35M
Gross Margin
100%
Operating Margin
-9,525.44%
Profit Margin
-9,145.5%
Debt to Equity
0.15
Operating Cash Flow
-$51M
Beta
0.92
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BRNS Overview
Vaccitech Public Limited Company is a biopharmaceutical company developing T-cell immunotherapeutics and vaccines for the treatment of infectious diseases and cancers. The company's pipeline includes VTP-300, in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection, VTP-200, in Phase 1/2a clinical trial for the treatment of human papilloma virus infection, and VTP-850, in Phase 1/2 clinical trial for the treatment of prostate cancer. Vaccitech was founded in 2016 and is headquartered in Oxford, UK.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BRNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BRNS ($2.43) is undervalued by 24.5% relative to our estimate of its Fair Value price of $3.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BRNS ($2.43) is significantly undervalued by 24.5% relative to our estimate of its Fair Value price of $3.22 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BRNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BRNS due diligence checks available for Premium users.
Be the first to know about important BRNS news, forecast changes, insider trades & much more!
BRNS News
Valuation
BRNS fair value
Fair Value of BRNS stock based on Discounted Cash Flow (DCF)
Price
$2.43
Fair Value
$3.22
Undervalued by
24.47%
BRNS ($2.43) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BRNS ($2.43) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BRNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BRNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.27x
Industry
15.41x
Market
40.97x
BRNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
5.8x
BRNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BRNS's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.3M
Profit Margin
0%
BRNS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BRNS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$214.5M
Liabilities
$27.5M
Debt to equity
0.15
BRNS's short-term assets ($156.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BRNS's short-term assets ($156.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BRNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.6M
Investing
$153.0k
Financing
$109.0k
BRNS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BRNS vs Biotech Stocks
Barinthus Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.